PMC:7784786 / 15432-15747 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"543","span":{"begin":208,"end":216},"obj":"Species"},{"id":"544","span":{"begin":306,"end":314},"obj":"Species"},{"id":"545","span":{"begin":0,"end":10},"obj":"Chemical"},{"id":"546","span":{"begin":232,"end":242},"obj":"Chemical"},{"id":"547","span":{"begin":56,"end":90},"obj":"Disease"}],"attributes":[{"id":"A543","pred":"tao:has_database_id","subj":"543","obj":"Tax:9606"},{"id":"A544","pred":"tao:has_database_id","subj":"544","obj":"Tax:9606"},{"id":"A545","pred":"tao:has_database_id","subj":"545","obj":"MESH:C000597346"},{"id":"A546","pred":"tao:has_database_id","subj":"546","obj":"MESH:C000597346"},{"id":"A547","pred":"tao:has_database_id","subj":"547","obj":"MESH:D060085"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Itolizumab was very safe and did not seem to exacerbate opportunistic secondary infections. Unfortunately, we did no measure neither the frequency nor the total amount of circulating T cells in these initial patients. The impact of itolizumab on circulating T cells are being implementing in new recruited patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T136","span":{"begin":0,"end":91},"obj":"Sentence"},{"id":"T137","span":{"begin":92,"end":217},"obj":"Sentence"},{"id":"T138","span":{"begin":218,"end":315},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Itolizumab was very safe and did not seem to exacerbate opportunistic secondary infections. Unfortunately, we did no measure neither the frequency nor the total amount of circulating T cells in these initial patients. The impact of itolizumab on circulating T cells are being implementing in new recruited patients."}